COVID-19 patients with poor outcomes had decreased levels of CD45RO−CD62L+ and CD45RO+CD62L+ Th cell during the acute stage compared to the reference ranges and the values observed in patients with favorable disease outcomes (Figure 3A,B). This evidence concerns the gene SELL and COVID-19.